全文获取类型
收费全文 | 223577篇 |
免费 | 5145篇 |
国内免费 | 125篇 |
专业分类
耳鼻咽喉 | 1525篇 |
儿科学 | 8496篇 |
妇产科学 | 4584篇 |
基础医学 | 23183篇 |
口腔科学 | 2281篇 |
临床医学 | 18481篇 |
内科学 | 40205篇 |
皮肤病学 | 1456篇 |
神经病学 | 21032篇 |
特种医学 | 10059篇 |
外科学 | 34236篇 |
综合类 | 3204篇 |
一般理论 | 75篇 |
预防医学 | 23797篇 |
眼科学 | 3552篇 |
药学 | 12567篇 |
中国医学 | 694篇 |
肿瘤学 | 19420篇 |
出版年
2023年 | 324篇 |
2022年 | 482篇 |
2021年 | 1214篇 |
2020年 | 771篇 |
2019年 | 1256篇 |
2018年 | 23078篇 |
2017年 | 18181篇 |
2016年 | 20414篇 |
2015年 | 1997篇 |
2014年 | 2362篇 |
2013年 | 3102篇 |
2012年 | 10276篇 |
2011年 | 24365篇 |
2010年 | 20574篇 |
2009年 | 13079篇 |
2008年 | 22163篇 |
2007年 | 24566篇 |
2006年 | 3436篇 |
2005年 | 4984篇 |
2004年 | 5878篇 |
2003年 | 6687篇 |
2002年 | 4731篇 |
2001年 | 1070篇 |
2000年 | 1197篇 |
1999年 | 909篇 |
1998年 | 750篇 |
1997年 | 681篇 |
1996年 | 521篇 |
1995年 | 482篇 |
1994年 | 406篇 |
1993年 | 398篇 |
1992年 | 574篇 |
1991年 | 647篇 |
1990年 | 629篇 |
1989年 | 544篇 |
1988年 | 477篇 |
1987年 | 457篇 |
1986年 | 416篇 |
1985年 | 405篇 |
1984年 | 352篇 |
1983年 | 309篇 |
1982年 | 225篇 |
1981年 | 186篇 |
1980年 | 200篇 |
1979年 | 227篇 |
1978年 | 188篇 |
1977年 | 175篇 |
1974年 | 215篇 |
1973年 | 181篇 |
1970年 | 162篇 |
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
91.
Statutory reimbursement agencies as well as private insurers throughout member states of the Organization for Economic Cooperation and Development (OECD) reimburse the cost of medicines on the basis of criteria that include robust clinical evidence, budget impact analysis, and incremental cost effectiveness. The Centers for Medicare and Medicaid Services (CMS) in the US are no exception to this rule and are, in principle, seeking to maximize benefit for their Medicare enrollees, whilst ensuring reasonable drug outlays for the small number of drugs that they reimburse. This paper provides a retrospective analysis of the way two functionally equivalent drugs are treated for reimbursement purposes by the CMS; the period under consideration was 2001–3. The two drugs, epoetin-α and darbepoetin-α, are used for the treatment of anemia in renal failure and in patients receiving chemotherapy. By reviewing the publicly available pharmacological and clinical data of epoetin-α and darbepoetin-α, the paper confirms the two drugs’ functional equivalence, despite their structural differences. The implications of dose conversion ratios and costs to Medicare are subsequently explored. It is argued that the issue of dose equivalence between epoetin-α and darbepoetin-α has significant implications for patients, practitioners, and payors. A payor’s perspective is adopted in this respect, whereby clinical evidence and pricing data are used simultaneously. Based on the clinical evidence, a dose conversion ratio for epoetin-α:darbepoetin-α is established, which achieves a comparable clinical effect for the two drugs and this is set to be <254IU:1μg. The incremental costs to Medicare are calculated subsequently. The Average Wholesale Price and the Outpatient Prospective Payment System rule that Medicare uses to reimburse providers are used and suggest that treatment of cancer patients with chemotherapy-related anemia with epoetin-α would save Medicare an estimated $US600 million each year. Patients would also benefit significantly in terms of lower co-payments for epoetin-α. The evidence is supportive of the decision made by the CMS to reimburse the two drugs at the rate reflecting the achievement of comparable clinical effects and therefore reducing the pass-through payments for darbepoetin-α to zero for the 2002–3 fiscal year. 相似文献
92.
Insulin dose-response characteristics for suppression of glycerol release and conversion to glucose in humans 总被引:7,自引:0,他引:7
To compare the dose-response characteristics for suppression of lipolysis and suppression of glucose production by insulin, 13 normal nonobese individuals were infused with insulin at rates of 0.1, 0.2, 0.4, 0.8, and 1.6 mU X kg-1 X min-1 while normoglycemia was maintained with the glucose clamp technique. Glucose appearance and glycerol appearance (taken as index of lipolysis) were measured isotopically with simultaneous infusions of 3-[3H]glucose and U-[14C]glycerol. Baseline glucose and glycerol rates of appearance were 14 +/- 0.5 and 1.7 +/- 0.2 mumol X kg-1 X min-1, respectively. Approximately 3% of plasma glucose originated from glycerol, and this accounted for approximately 50% of glycerol disposal. During the insulin infusions, arterial insulin (basal, 9.8 +/- 0.6 microU/ml) increased to 14 +/- 0.5, 20 +/- 0.5, 31 +/- 1, 58 +/- 2, and 104 +/- 6 microU/ml; calculated portal venous insulin (basal, 24 +/- 2 microU/ml) increased to 26 +/- 1, 32 +/- 3, 70 +/- 4, and 115 +/- 6 microU/ml. The rate of glucose appearance was suppressed 100%, whereas the rate of appearance of glycerol was maximally suppressed only 85%. Nevertheless, the insulin concentration that produced half-maximal suppression of glucose appearance was twice as great as that required for half-maximal suppression of glycerol appearance (26 +/- 2 vs. 13 +/- 2 microU/ml, P less than .001). Insulin decreased both the absolute rate of glycerol conversion to plasma glucose and the percent of glycerol disposal appearing in plasma glucose (both P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
93.
Objective: To study the diagnostic value of T2^*-weighted first-pass perfusion imaging in breast tumors. Methods: We analyzed the magnetic resonance imaging (MRI) information along with the pathological and immunohistochemistry results. Magnetic resonance imaging was performed in 28 patients with breast tumor. The time to signal intensity curves were generated according to the T2^*-weighted first-pass perfusion imaging. The curve's maximal signal intensity drop rate and maximal signal intensity decrease time were analyzed and compared with the pathological diagnoses after surgery. Results: Malignant breast lesions showed higher maximal signal intensity drop rate (44.69% ± 17.07 vs. 17.22% ±7.49, P 〈 0.001) than benign lesions, but there was no significant difference of maximal signal decrease time between those two lesions (23.94 s ± 4.92 vs. 20.02 s ± 6.83, P 〉 0.05). Conclusion: The T2^*-weighted first-pass perfusion imaging has enough sensitivity and specificity in breast tumor diagnosis. 相似文献
94.
95.
96.
Stimulation by mitogens and neuronal membranes of lymphocytes from patients with motor neurone disease 总被引:1,自引:0,他引:1
Jaqueline Aspin Roger Harrison Ahmed Jehanli George Lunt Malcolm Campbell 《Journal of neuroimmunology》1986,11(1):31-40
Stimulation of lymphocytes from motor neurone disease patients by either concanavalin A or PHA was shown to be significantly depressed relative to that from normal controls, as assayed by incorporation of [3H]thymidine or [3H]leucine or by glucose uptake. Corresponding significant differences were not shown by assays based upon incorporation of [3H]uridine or of lactate release. Lymphocytes from 4 out of 14 motor neurone disease patients showed a blastogenic response to membranes from rat spinal cord cells, compared with those from 0 out of 9 normal controls. These results not only suggest the possibility of an impaired cellular immune control in MND patients but also indicate the presence of lymphocytes sensitised specifically to neuronal membrane components. 相似文献
97.
98.
Catherine Guette Christian Legros Guewen Tournois Max Goyffon Marie-Louise Célérier 《Toxicon》2006,47(6):640-649
In order to establish a venom fingerprint and a peptide profile of the Lasiodora parahybana tarantula venom gland, we used conventional methods such as reversed phase liquid chromatography coupled to an electrospray-ionisation hybrid quadrupole time of flight mass spectrometer (LC/ESI-QqTOFMS), matrix-assisted laser desorption/ionization time-of-flight-MS (MALDI-TOFMS) and direct study of L. parahybana venom by nanospray-ionization QqTOFMS (nanoESI-QqTOFMS) and a new technology for the direct analysis of fresh tissues using MALDI-TOFMS. The analysis of the crude venom allowed the characterization of specific juvenile and adult biomarkers. In situ MALDI analysis of L. parahybana venom gland sections revealed different peptide expression levels all along the gland and non-processed peptide precursors, demonstrating the power of the method for the dynamic investigation of peptide evolution in the venom gland of spiders. 相似文献
99.
100.
Chad G. Ball Andrew W. Kirkpatrick Matthew Smith Robert H. Mulloy Leonard Tse Ian B. Anderson 《European journal of trauma and emergency surgery》2007,33(5):550-552
Abstract We report a case of SMV injury in a critically ill patient. The patient was a 19-year-old woman involved in a motor vehicle
collision. Her injuries included grade II splenic and renal lacerations, devascularized and lacerated right and transverse
colon, a transected transverse mesocolon, a massive shear injury of her abdominal wall, and two partial SMV transections.
At initial damage control laparotomy, the SMV was ligated, the devascularized bowel resected and a temporary abdominal closure
applied. At re-operation, a mesocaval shunt using saphenous vein was employed. The shunt failed and the patient required a
saphenous vein jump graft. Although visceral vascular injuries are rare, ligation of the SMV in a damage control situation
is acceptable. This case study is the first to discuss appropriate treatment when interruption to a patient's collateral visceral
venous drainage limits the surgeon’s ability to ligate. In these situations, bypass shunts may be successful. 相似文献